Stockpolly
Search
Delisting risk
PSTV · NASDAQ · Biotechnology

Plus Therapeutics (PSTV)

Develops targeted radiotherapeutics and CNSide diagnostics for central nervous system cancers.

$3.87
At close−0.13 (−3.25%)
Watchlist

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue112111111110
Cost of revenue000000000000
Gross profit11111111111−1
455555436789
Research & development233332212334
222223323455
General & administrative022223323455
Other expenses000000000000
Operating income−3−4−3−4−4−4−4−2−4−6−7−9
000110−1470000
Interest income000000000000
Interest expense000400400300
Other non-operating income000−4−1010−70−300
Income before tax−3−4−3−3−3−4−175−4−6−7−9
Net income from continuing operations−3−4−3−3−3−4−175−4−6−7−9
Net income−3−4−3−3−3−4−175−4−6−7−9
EPS, basic−$25,000.00−$21,250.00−$18,750.00−$11,250.00−$9,250.00−$16,500.00−$29,750.00$615.00−$1,030.00−$1.04−$1.05−$1.31
EPS, diluted−$25,000.00−$21,250.00−$18,750.00−$6,750.00−$9,250.00−$16,500.00−$29,750.00−$162.50−$1.00−$1.05−$1.05−$1.31
Weighted average shares, basic0——————00377
Weighted average shares, diluted0——————00377
EBITDA−3−4−31−3−4−135−4−2−7−9
Depreciation & amortization000000000000
EBIT−3−4−31−3−4−145−4−2−7−9